Product Detail
Galanthamine-O-methyl-d3 Hydrobromide
Stable Isotopes
Stock Status: Enquire
Live
For Research & Analytical Purposes. Not for Personal use.
Category
Stable Isotopes
API Family
--
Storage
Refer MSDS for complete information.
Hazard Information
Refer MSDS for complete information.
Galanthamine-O-methyl-d3 Hydrobromide Product Information
Galanthamine-O-methyl-d3 Hydrobromide is listed under Stable Isotopes. It is associated with and is intended for analytical research, quality control and pharmaceutical reference standard applications. The product is supplied by Clearsynth under CAT No. CS-T-97487.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight and product enquiry details.
Technical Data
Product Name
Galanthamine-O-methyl-d3 Hydrobromide
CAS No.
-
CAT No.
CS-T-97487
Molecular Formula
C17H19D3BrNO3
Molecular Weight
371.28
Category
Storage Condition
Refer MSDS for complete information.
IUPAC Name
Galanthamine-O-methyl-d3 Hydrobromide
Hazard Compound
Refer MSDS for complete information.
Description
Overview
"Galanthamine-O-methyl-d3 Hydrobromide is the labeled analogue of Galanthamine Hydrobromide (G188500), a selective acetylcholinesterase inhibitor. A therapeutic agent for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism."
Synonyms
"(4aS,6R,8aS)-4a,5,9,10,11,12-hexahydro-3-methoxy-d3-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol Hydrobromide; Galanthamine-d3 Hydrobromide; (-)-Galantamine-d3 Hydrobromide; (-)-Galanthamine-d3 Hydrobromide; Galantamine-d3 Hydrobromide; Galanthamin"
Application Notes
"Galanthamine-O-methyl-d3 Hydrobromide is the labeled analogue of Galanthamine Hydrobromide (G188500), a selective acetylcholinesterase inhibitor. A therapeutic agent for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism."
References
"Friess, S.L., et al.: Toxicol. Appl. Pharmacol., 3, 347 (1961); Bickel, U., et al.: Clin. Pharmacol. Ther., 50, 420 (1991); Harvey, A.L., et al.: Pharmacol. Ther., 68, 113 (1995)"